The present study evaluated safety, efficacy, and prognostic factors for 90 Y-yttrium microsphere radioembolization of unresectable liver metastases from breast cancer. Methods: Eighty-one patients were treated with radioembolization. Acute toxicity was monitored through daily physical examination and serum tests until 3 d after radioembolization; late toxicity was evaluated until 12 wk after radioembolization. Overall survival and response according to 18 F-FDG PET (.30% decrease of tracer uptake) and CA15-3 serum level (any decline) were recorded. Pretherapeutic characteristics, including pretreatment history, liver function tests, and PET/CT parameters, were assessed by univariate and subsequent multivariate Cox regression for predicting patient survival. Results: A toxicity grade of 3 or more based on clinical symptoms, bilirubin, ulcer, pancreatitis, ascites, or radioembolization-induced liver disease occurred in 10% or less of patients. Two patients eventually died from radioembolization-induced liver disease. Sequential lobar treatment and absence of prior angiosuppressive therapy were both associated with a lower rate of serious adverse events. On the basis of PET/CA15-3 criteria, 52/61% of patients responded to treatment. Median overall survival after radioembolization was 35 wk (interquartile range, 41 wk). Pretherapeutic tumor burden of the liver greater than 50% or more (P , 0.001; hazard ratio, 5.67; 95% confidence interval, 2.41-13.34) and a transaminase toxicity grade of 2 or more (P 5 0.009; hazard ratio, 2.15; 95% confidence interval, 1.21-3.80) independently predicted short survival. Conclusion: Radioembolization for breast cancer liver metastases shows encouraging local response rates with low incidence of serious adverse events, especially in those patients with sequential lobar treatment or without prior angiosuppressive therapy. High hepatic tumor burden and liver transaminase levels at baseline indicate poor outcome.
Treating elderly and frail patients with DLBCL is a unique therapeutic challenge since standard chemotherapy is not applicable. We report the outcome of nine patients deemed unable to tolerate chemotherapy who were treated with rituximab plus prednisone with or without radiotherapy at our institute between 2012 and 2021. Median age was 82 years (range 75 - 93). While four of our patients had no clinical benefit, three patients profited notably from therapy and another two achieved a mixed response. Median OS was 7.0 months and median PFS was 3.2 months. Median PFS in responders and non-responders was 25.1 months and 2 days, respectively. Positive outcomes were associated with ECOG performance status < 4, non-severe comorbidities, mainly localized disease, IPI non high risk and those who received radiation to the main tumor mass. Our data suggests that selected frail patients may benefit from therapy with rituximab plus prednisone.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.